Hans Wigzell's Insider Trades & SAST Disclosures
Hans Wigzell's most recent trade in Sarepta Therapeutics Inc was a trade of 4,792 Stock Options (right to buy) done . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Hans Wigzell.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 4,792 | 4,792 | - | - | Stock Options (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 2,383 | 25,223 (0%) | 0% | - | Common Stock | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2024 | 10,500 | 0 | - | - | Stock Options (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Sale of securities on an exchange or to another person at price $ 124.84 per share. | 12 Dec 2024 | 10,500 | 22,840 (0%) | 0% | 124.8 | 1,310,820 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.71 per share. | 12 Dec 2024 | 10,500 | 33,340 (0%) | 0% | 13.7 | 143,955 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.90 per share. | 08 Mar 2024 | 15,000 | 37,840 (0%) | 0% | 13.9 | 208,500 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 15,000 | 0 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Sale of securities on an exchange or to another person at price $ 123.10 per share. | 08 Mar 2024 | 11,745 | 22,940 (0%) | 0% | 123.1 | 1,445,810 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Sale of securities on an exchange or to another person at price $ 123.85 per share. | 08 Mar 2024 | 3,155 | 34,685 (0%) | 0% | 123.9 | 390,747 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Sale of securities on an exchange or to another person at price $ 122.39 per share. | 08 Mar 2024 | 100 | 22,840 (0%) | 0% | 122.4 | 12,239 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 3,679 | 3,679 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 1,846 | 22,840 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.03 per share. | 04 Aug 2023 | 15,000 | 35,994 (0%) | 0% | 29.0 | 435,450 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Sale of securities on an exchange or to another person at price $ 106.72 per share. | 04 Aug 2023 | 15,000 | 20,994 (0%) | 0% | 106.7 | 1,600,800 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2023 | 15,000 | 0 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 3,257 | 3,257 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 1,523 | 20,994 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 5,077 | 5,077 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 2,953 | 19,471 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.92 per share. | 08 Mar 2021 | 10,000 | 26,518 (0%) | 0% | 34.9 | 349,200 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2021 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Sale of securities on an exchange or to another person at price $ 83.51 per share. | 08 Mar 2021 | 10,000 | 16,518 (0%) | 0% | 83.5 | 835,100 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 5,518 | 5,518 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 2,726 | 16,518 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.92 per share. | 10 Aug 2020 | 10,000 | 23,792 (0%) | 0% | 34.9 | 349,200 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Sale of securities on an exchange or to another person at price $ 158.95 per share. | 10 Aug 2020 | 9,223 | 14,569 (0%) | 0% | 159.0 | 1,465,996 | Common Stock |
| Sarepta Therapeutics Inc | Hans Wigzell | Director | Sale of securities on an exchange or to another person at price $ 159.65 per share. | 10 Aug 2020 | 777 | 13,792 (0%) | 0% | 159.6 | 124,048 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges